Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-oflife results from the phase 3 KEYNOTE-590 study | JOURNAL OF CLINICAL ONCOLOGY |